WEDNESDAY, DECEMBER 3, 2008

Location: Cabinet/Judiciary Suite; Hyatt Regency Bethesda

6:00 p.m. – 9:30 p.m.  Young Urologic Oncologist (Y.U.O.) Dinner Program

6:30 p.m. – 7:00 p.m.  Update on SUO Long-Range Planning Activities
  Martin E. Gleave, MD
  The Prostate Centre at VGH

7:00 p.m. – 7:30 p.m.  Young Urologic Oncologists (Y.U.O.) Investigator Award Presentation
  Jodi Kathleen Maranchie, MD
  University of Pittsburgh

7:30 p.m. – 8:45 p.m.  Young Urologic Oncologists (Y.U.O.) Podium Presentations
  Moderator: Jonathan Coleman, MD
  Memorial Sloan-Kettering Cancer Center

7:30 p.m.  #1  MULTI-INSTITUTIONAL VALIDATION OF THE PREDICTIVE VALUE OF KI-67 LABELING INDEX IN PATIENTS WITH URINARY BLADDER CANCER
  Vitaly Margulis, MD, Yair Lotan, MD, Pierre Karakiewicz, MD, Yves Fradet, MD, Raheela Ashfaq, MD, Umberto Capitanio, MD, Francesco Montorsi, MD, Patrick Bastian, MD, Matthew Nielsen, MD, Stefan Muller, MD, Jerome Rigaud, MD, Seth Lerner, MD, George Netto, MD, Arthur Sagalowsky, MD and Shahrokh Shariat, MD (Presented By: Vitaly Margulis)

7:45 p.m.  #2  CYP17 POLYMORPHISMS AND PROSTATE CANCER RISK AND MORTALITY
  Jonathan L. Wright1,2, Daniel W. Lin1,2, Erika M. Kwon4, Suzanne Kolb2, Ziding Feng3, Joseph Koopmeiners1, Elaine A. Ostrander4, Janet L. Stanford2,5 (Presented By: Jonathan Wright)
  1Department of Urology, University of Washington School of Medicine, Seattle, WA; 2Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; 3Department of Biostatistics, University of Washington School of Public Health, Seattle, WA; 4Cancer Genetics Branch, National Human Genome Research Institute, Bethesda, MD; 5Department of Epidemiology, University of Washington School of Public Health, Seattle, WA

8:00 p.m.  #3  IMAGE GUIDED PHOTOTHERMAL TARGETED THERAPY FOR LOW RISK LOCALIZED PROSTATE CANCER
  Uri Lindner, MD2, Massom A. Haider, MD, FRCPC1, Robert A. Weersink, PhD1, Sean R.H. Davidson, MASc1, Mark R. Gertner, PhD1, Mostafa Atri, MD, FRCPC3 and John Trachtenberg, MD, FRCSC1 (Presented By: Uri Lindner)
  1Princess Margaret Hospital, University of Toronto; 2Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada; 3Sunnybrook Health Science Centre, University of Toronto, Toronto, ON, Canada

8:45 p.m. – 9:30 p.m.  Y.U.O. Business Meeting

Continues on next page
FRIDAY, DECEMBER 5, 2008
Location: NIH, Natcher Center

8:00 a.m. – 8:30 a.m. Young Urologic Oncologists (YUO)
Moderator: Jonathan Coleman, MD
Memorial Sloan-Kettering Cancer Center

Selected YUO Podium Abstract Presentations

8:00 a.m. # 4 UPREGULATION OF TRAG3 (TAXOL RESISTANCE ASSOCIATED GENE 3) IS ASSOCIATED WITH ADVANCED BLADDER CANCER (BCA)
Jose Karam, MD¹, Sandra Huang¹, Jinhai Fan¹, Jennifer Stanfield¹, Roger Schultz², Rey-Chen Pong³, Xiankai Sun³, Xian-Jin Xie³, Arthur Sagalowsky⁴ and Jer-Tsong Hsieh¹ (Presented By: Jose Karam)
¹Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX; ²Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX; ³Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX; ⁴Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX

8:10 a.m. # 5 COMPARISON OF PRIMARY AND METASTATIC TO LYMPH NODE CELL LINES FROM THE SAME PATIENTS
Kiranpreet Khurana, Nick W. Liu, BS, Ariel Reinish, Youfeng Yang, PhD, Vladimir Valera, PhD, Cathy Vocke, PhD, Peter A. Pinto, MD, W. Marston Linehan, MD and Gennady Bratslavsky, MD (Presented By: Kiranpreet Khurana).
Bethesda, MD

8:20 a.m. # 6 CLINICAL OUTCOMES IN CLINICAL STAGE III NSGCT PATIENTS WHO ACHIEVE A COMPLETE RADIOGRAPHIC RESPONSE TO CHEMOTHERAPY AT THE SITE OF EXTRA-RETROPERITONEAL DISEASE
Timothy A. Masterson, MD, Brett S. Carver, MD, Robert J. Motzer, MD, George J. Bosl, MD and Joel Sheinfeld, MD (Presented By: Timothy A. Masterson)
MSKCC, New York, NY